{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:44:52Z","timestamp":1789771492918,"version":"4.0.1"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.antiviral.2022.105461","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T02:16:03Z","timestamp":1668392163000},"page":"105461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Hepatitis D virus: Improving virological knowledge to develop new treatments"],"prefix":"10.1016","volume":"209","author":[{"given":"Pierre","family":"Khalfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7345-6840","authenticated-orcid":false,"given":"Patrick T.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Majzoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2022.105461_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006002.pub2","article-title":"Interferon alpha for chronic hepatitis D","author":"Abbas","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.antiviral.2022.105461_bib2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4254\/wjh.v8.i14.625","article-title":"Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: a randomized trial","volume":"8","author":"Abbas","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2016.10.006","article-title":"HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes","volume":"136","author":"Alfaiate","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105461_bib4","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S0168-8278(18)30398-2","article-title":"Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with Tenofovir in chronic HBV\/HDV infected patients: interim results from a multicenter, open-label phase 2b clinical trial","volume":"68","author":"Allweiss","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156667","article-title":"Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive Bangladeshi patients with HBeAg+ chronic hepatitis B infection","volume":"11","author":"Al-Mahtab","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2022.105461_bib6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2468-1253(19)30190-6","article-title":"Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure","volume":"4","author":"Asselah","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib7","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/liv.14950","article-title":"Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life","volume":"41","author":"Asselah","year":"2021","journal-title":"Liver Int."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2022.105461_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13673","article-title":"Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?","volume":"38","author":"Asselah","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2022.105461_bib9","doi-asserted-by":"crossref","first-page":"9786","DOI":"10.1128\/JVI.79.15.9786-9798.2005","article-title":"Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition","volume":"79","author":"Barrera","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep4.1633","article-title":"Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hepatitis B virus\/hepatitis delta virus coinfection","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.antiviral.2022.105461_bib12","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1128\/jvi.70.8.4986-4995.1996","article-title":"Identification and characterization of a hepatitis delta virus RNA transcriptional promoter","volume":"70","author":"Beard","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib13","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2019907118","article-title":"Diversification of mammalian deltaviruses by host shifting","volume":"118","author":"Bergner","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2022.105461_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2019.02.009","article-title":"Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells","volume":"164","author":"Blanchet","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105461_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2016.04.013","article-title":"First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B","volume":"65","author":"Blank","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/jvi.58.3.945-950.1986","article-title":"Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope","volume":"58","author":"Bonino","year":"1986","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib18","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.1128\/JVI.76.20.10465-10472.2002","article-title":"A prenylation inhibitor prevents production of infectious hepatitis delta virus particles","volume":"76","author":"Bordier","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib19","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1172\/JCI17704","article-title":"In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus","volume":"112","author":"Bordier","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2022.105461_bib20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1126\/science.6197756","article-title":"A replication cycle for viroids and other small infectious RNA's","volume":"223","author":"Branch","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2022.105461_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/hep4.1043","article-title":"Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection","volume":"1","author":"Canini","year":"2017","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.antiviral.2022.105461_bib22","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/infdis\/jiaa517","article-title":"No evidence of hepatitis C virus (HCV)\u2013Assisted hepatitis D virus propagation in a large cohort of HCV-positive blood donors","volume":"223","author":"Cappy","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105461_bib23","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1128\/jvi.69.12.7593-7600.1995","article-title":"Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA","volume":"69","author":"Casey","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00280-010-1488-5","article-title":"Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors","volume":"67","author":"Castaneda","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.antiviral.2022.105461_bib25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib26","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2015.12.018","article-title":"Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B)","volume":"64","author":"Chan","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib27","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/JVI.01758-07","article-title":"Transcription of hepatitis delta virus RNA by RNA polymerase II","volume":"82","author":"Chang","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vez021","article-title":"Novel hepatitis D-like agents in vertebrates and invertebrates","volume":"5","author":"Chang","year":"2019","journal-title":"Virus Evol."},{"key":"10.1016\/j.antiviral.2022.105461_bib29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/hep.31453","article-title":"Preliminary evidence for hepatitis delta virus exposure in patients who are apparently not infected with hepatitis B virus","volume":"73","author":"Chemin","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13099-021-00462-0","article-title":"Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis","volume":"13","author":"Chen","year":"2021","journal-title":"Gut Pathog."},{"key":"10.1016\/j.antiviral.2022.105461_bib31","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1128\/JVI.72.5.3684-3690.1998","article-title":"Hepatitis delta antigen mediates the nuclear import of hepatitis delta virus RNA","volume":"72","author":"Chou","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00280-007-0646-x","article-title":"A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors","volume":"62","author":"Chow","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.antiviral.2022.105461_bib192","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"72","author":"Cornberg","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib34","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1128\/JVI.02467-08","article-title":"Hepatitis delta antigen requires a minimum length of the hepatitis delta virus unbranched rod RNA structure for binding","volume":"83","author":"Defenbaugh","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.07.016","article-title":"Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension","author":"Degasperi","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41586-021-04332-2","article-title":"Petabase-scale sequence alignment catalyses viral discovery","volume":"602","author":"Edgar","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105461_bib37","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/jac\/dkg490","article-title":"Prenylation inhibitors: a novel class of antiviral agents","volume":"52","author":"Einav","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2022.105461_bib38","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.21112","article-title":"Characterization of a hepatitis B and hepatitis delta virus receptor binding site","volume":"43","author":"Engelke","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib39","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S0618-8278(19)30058-1","article-title":"PS-052-End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection","volume":"70","author":"Etzion","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib40","first-page":"370","article-title":"Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver","volume":"67","year":"2017","journal-title":"EASL 2017 Clinical Practice Guidelines Manag. Hepatitis B virus Infection. J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib41","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2022.105461_bib42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/26912","article-title":"Crystal structure of a hepatitis delta virus ribozyme","volume":"395","author":"Ferr\u00e9-D\u2019Amar\u00e9","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105461_bib43","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1186\/s40064-016-2920-z","article-title":"A randomized, controlled study of peginterferon lambda-1a\/ribavirin \u00b1 daclatasvir for hepatitis C virus genotype 2 or 3","volume":"5","author":"Foster","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.antiviral.2022.105461_bib44","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1128\/JVI.00430-14","article-title":"Envelope proteins derived from naturally integrated hepatitis B virus DNA support assembly and release of infectious hepatitis delta virus particles","volume":"88","author":"Freitas","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib45","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/gutjnl-2017-314713","article-title":"Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo","volume":"68","author":"Giersch","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2022.105461_bib46","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/liv.14677","article-title":"Murine hepatocytes do not support persistence of Hepatitis D virus mono-infection in vivo","volume":"41","author":"Giersch","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2022.105461_bib47","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1038\/s41598-017-03946-9","article-title":"Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV\/HDV infected humanized mice","volume":"7","author":"Giersch","year":"2017","journal-title":"Sci. Rep."},{"issue":"22","key":"10.1016\/j.antiviral.2022.105461_bib48","article-title":"Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication","volume":"S0168\u20138278","author":"Gillich","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106562","article-title":"Hepatitis delta treatment with bulevirtide in real life: a case report","volume":"59","author":"Giordan","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.antiviral.2022.105461_bib50","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.1598578","article-title":"Identification of a prenylation site in delta virus large antigen","volume":"256","author":"Glenn","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2022.105461_bib51","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.1840060415","article-title":"Natural course of delta superinfection in chronic hepatitis B virus-infected patients: histopathologic study with multiple liver biopsies","volume":"6","author":"Govindarajan","year":"1986","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.virol.2009.02.007","article-title":"The hepatitis delta virus RNA genome interacts with the human RNA polymerases I and III","volume":"386","author":"Greco-Stewart","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2022.105461_bib53","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1128\/JVI.00443-14","article-title":"Hepatitis delta antigen requires a flexible quasi-double-stranded RNA structure to bind and condense hepatitis delta virus RNA in a ribonucleoprotein complex","volume":"88","author":"Griffin","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib54","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/JVI.79.3.1613-1622.2005","article-title":"Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein","volume":"79","author":"Gripon","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib55","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1128\/JVI.76.8.3709-3719.2002","article-title":"Parameters of human hepatitis delta virus genome replication: the quantity, quality, and intracellular distribution of viral proteins and RNA","volume":"76","author":"Gudima","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib56","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1002\/hep.27357","article-title":"Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling","volume":"60","author":"Guedj","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib57","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/135965350501000603","article-title":"Two-year interferon therapy with or without ribavirin in chronic delta hepatitis","volume":"10","author":"Gunsar","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2022.105461_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022415","article-title":"Interferon impedes an early step of hepatitis delta virus infection","volume":"6","author":"Han","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2022.105461_bib59","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jhep.2004.06.025","article-title":"Interferon-alpha stimulation of liver cells enhances hepatitis delta virus RNA editing in early infection","volume":"41","author":"Hartwig","year":"2004","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2893.2005.00663.x","article-title":"The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells","volume":"13","author":"Hartwig","year":"2006","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2022.105461_bib61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jmv.1890270107","article-title":"The size of the hepatitis delta agent","volume":"27","author":"He","year":"1989","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11908-012-0307-z","article-title":"Treatment options for hepatitis delta virus infection","volume":"15","author":"Heidrich","year":"2013","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.antiviral.2022.105461_bib63","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib64","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2022.105461_bib65","doi-asserted-by":"crossref","first-page":"E1486","DOI":"10.3390\/cells9061486","article-title":"Hepatitis B virus entry into cells","volume":"9","author":"Herrscher","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.antiviral.2022.105461_bib66","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/pathogens11050517","article-title":"Efficacy and safety of bulevirtide plus tenofovir disoproxil fumarate in real-world patients with chronic hepatitis B and D Co-infection","volume":"11","author":"Herta","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.antiviral.2022.105461_bib67","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00014-19","article-title":"Identification of a novel deltavirus in Boa constrictors","volume":"10","author":"Hetzel","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2022.105461_bib68","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1128\/jvi.64.7.3192-3198.1990","article-title":"Hepatitis delta virus genome replication: a polyadenylated mRNA for delta antigen","volume":"64","author":"Hsieh","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/v9030056","article-title":"Complete and incomplete hepatitis B virus particles: formation, function, and application","volume":"9","author":"Hu","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2022.105461_bib70","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1128\/jvi.68.5.2958-2964.1994","article-title":"Isoprenylation masks a conformational epitope and enhances trans-dominant inhibitory function of the large hepatitis delta antigen","volume":"68","author":"Hwang","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib71","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/veab003","article-title":"Identification of novel avian and mammalian deltaviruses provides new insights into deltavirus evolution","volume":"7","author":"Iwamoto","year":"2021","journal-title":"Virus Evol."},{"key":"10.1016\/j.antiviral.2022.105461_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-Results of A \u201creal world\u201d Study","author":"Jachs","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2022.105461_bib73","doi-asserted-by":"crossref","first-page":"8184","DOI":"10.1038\/s41598-021-87679-w","article-title":"Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide\/nucleoside analogues","volume":"11","author":"Jang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2022.105461_bib74","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1128\/JVI.76.8.3819-3827.2002","article-title":"Increased RNA editing and inhibition of hepatitis delta virus replication by high-level expression of ADAR1 and ADAR2","volume":"76","author":"Jayan","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib75","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/JVI.73.4.3351-3358.1999","article-title":"Mutations in the carboxyl-terminal domain of the small hepatitis B virus envelope protein impair the assembly of hepatitis delta virus particles","volume":"73","author":"Jenna","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib76","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: first approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2022.105461_bib77","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.cgh.2015.05.029","article-title":"Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome","volume":"13","author":"Keskin","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib78","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","article-title":"Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial","volume":"15","author":"Koh","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105461_bib79","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/S0168-8278(20)30774-1","article-title":"A phase 2 study of peginterferon lambda, lonafarnib and ritonavir for 24 Weeks: end-of-treatment results from the LIFT HDV study","volume":"73","author":"Koh","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib80","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0168-8278(17)30464-6","article-title":"A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis \u2013 end of study results from the LOWR HDV-3 study","volume":"66","author":"Koh","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib81","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/JVI.80.10.4648-4655.2006","article-title":"A tryptophan-rich motif in the carboxyl terminus of the small envelope protein of hepatitis B virus is central to the assembly of hepatitis delta virus particles","volume":"80","author":"Komla-Soukha","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib82","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/323558a0","article-title":"The hepatitis delta (delta) virus possesses a circular RNA","volume":"323","author":"Kos","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105461_bib83","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.antiviral.2022.105461_bib84","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s00705-020-04731-2","article-title":"2020 taxonomic update for phylum Negarnaviricota (Riboviria: orthornavirae), including the large orders Bunyavirales and Mononegavirales","volume":"165","author":"Kuhn","year":"2020","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib85","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1128\/jvi.63.5.1945-1950.1989","article-title":"Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen","volume":"63","author":"Kuo","year":"1989","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib86","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1128\/jvi.62.7.2394-2402.1988","article-title":"A transcriptionally defective long terminal repeat within an endogenous copy of mouse mammary tumor virus proviral DNA","volume":"62","author":"Kuo","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib87","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.drudis.2015.10.021","article-title":"IFN-lambda therapy: current status and future perspectives","volume":"21","author":"Lasfar","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.antiviral.2022.105461_bib88","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3201\/eid1209.060112","article-title":"Eighth major clade for hepatitis delta virus","volume":"12","author":"Le Gal","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105461_bib89","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1126\/science.1083338","article-title":"Hypermutation of HIV-1 DNA in the absence of the Vif protein","volume":"300","author":"Lecossier","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2022.105461_bib90","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/viro.1994.1109","article-title":"Isoprenylation of large hepatitis delta antigen is necessary but not sufficient for hepatitis delta virus assembly","volume":"199","author":"Lee","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2022.105461_bib91","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature06290","article-title":"Molecular basis of RNA-dependent RNA polymerase II activity","volume":"450","author":"Lehmann","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105461_bib92","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrgastro.2016.126","article-title":"Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options","volume":"13","author":"Lempp","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib93","first-page":"4947","article-title":"Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice","volume":"58","author":"Liu","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2022.105461_bib94","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2021.10.012","article-title":"Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis","volume":"76","author":"Loglio","year":"2022","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2022.105461_bib95","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/liv.14838","article-title":"New therapies for hepatitis delta virus infection","volume":"41","author":"Loureiro","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2022.105461_bib96","first-page":"13","article-title":"Identification of promoters of hepatitis delta virus RNA transcription on hepatitis delta virus cDNA","volume":"382","author":"Macnaughton","year":"1993","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.antiviral.2022.105461_bib97","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1128\/JVI.74.16.7375-7380.2000","article-title":"The large delta antigen of hepatitis delta virus potently inhibits genomic but not antigenomic RNA synthesis: a mechanism enabling initiation of viral replication","volume":"74","author":"Modahl","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib98","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1128\/JVI.72.7.5449-5456.1998","article-title":"Transcription of hepatitis delta antigen mRNA continues throughout hepatitis delta virus (HDV) replication: a new model of HDV RNA transcription and replication","volume":"72","author":"Modahl","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib99","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1128\/MCB.20.16.6030-6039.2000","article-title":"RNA-Dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases","volume":"20","author":"Modahl","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.antiviral.2022.105461_bib100","doi-asserted-by":"crossref","first-page":"9087","DOI":"10.1128\/JVI.75.19.9087-9095.2001","article-title":"The conserved serine 177 in the delta antigen of hepatitis delta virus is one putative phosphorylation site and is required for efficient viral RNA replication","volume":"75","author":"Mu","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib101","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.virol.2003.10.024","article-title":"The small delta antigen of hepatitis delta virus is an acetylated protein and acetylation of lysine 72 may influence its cellular localization and viral RNA synthesis","volume":"319","author":"Mu","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2022.105461_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059611","article-title":"Targeted induction of interferon-\u03bb in humanized chimeric mouse liver abrogates hepatotropic virus infection","volume":"8","author":"Nakagawa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2022.105461_bib103","doi-asserted-by":"crossref","first-page":"a021550","DOI":"10.1101\/cshperspect.a021550","article-title":"Hepatitis D virus coinfection and superinfection","volume":"4","author":"Negro","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.antiviral.2022.105461_bib104","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2022.105461_bib105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2893.2005.00601.x","article-title":"Treatment of hepatitis D","volume":"12","author":"Niro","year":"2005","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2022.105461_bib106","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.13734","article-title":"HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response","volume":"44","author":"Niro","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2022.105461_bib107","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1128\/AAC.01005-13","article-title":"Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105461_bib108","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1128\/AAC.01003-13","article-title":"Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2022.105461_bib109","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.79.2.1142-1153.2005","article-title":"Roles of carboxyl-terminal and farnesylated residues in the functions of the large hepatitis delta antigen","volume":"79","author":"O'Malley","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib110","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1074\/jbc.271.9.4569","article-title":"The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells","volume":"271","author":"Otto","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2022.105461_bib111","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/0016-5085(91)90404-9","article-title":"Patterns of hepatitis delta virus reinfection and disease in liver transplantation","volume":"101","author":"Ottobrelli","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2022.105461_bib112","doi-asserted-by":"crossref","first-page":"17977","DOI":"10.1073\/pnas.2006750117","article-title":"Mammalian deltavirus without hepadnavirus coinfection in the neotropical rodent Proechimys semispinosus","volume":"117","author":"Paraskevopoulou","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2022.105461_bib113","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/s41467-019-10117-z","article-title":"Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo","volume":"10","author":"Perez-Vargas","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.antiviral.2022.105461_bib114","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3390\/v13071207","article-title":"HDV-like viruses","volume":"13","author":"P\u00e9rez-Vargas","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2022.105461_bib115","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/350434a0","article-title":"A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA","volume":"350","author":"Perrotta","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105461_bib116","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nbt1389","article-title":"Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein","volume":"26","author":"Petersen","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2022.105461_bib117","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/jvh.13385","article-title":"Hepatitis delta virus propagation enabled by hepatitis C virus\u2014Scientifically intriguing, but is it relevant to clinical practice?","volume":"28","author":"Pfl\u00fcger","year":"2021","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2022.105461_bib118","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1128\/MCB.18.4.1919","article-title":"Hepatitis delta virus RNA editing is highly specific for the amber\/W site and is suppressed by hepatitis delta antigen","volume":"18","author":"Polson","year":"1998","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.antiviral.2022.105461_bib119","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.22654","article-title":"Hepatitis delta virus inhibits alpha interferon signaling","volume":"49","author":"Pugnale","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib120","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/hep.29737","article-title":"Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks","volume":"67","author":"Quinet","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib121","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1073\/pnas.97.1.424","article-title":"A host-specific function is required for ligation of a wide variety of ribozyme-processed RNAs","volume":"97","author":"Reid","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2022.105461_bib122","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gut.18.12.997","article-title":"Immunofluorescence detection of new antigen-antibody system (delta\/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers","volume":"18","author":"Rizzetto","year":"1977","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2022.105461_bib123","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(79)92561-3","article-title":"Incidence and significance of antibodies to delta antigen in hepatitis b virus infection","volume":"314","author":"Rizzetto","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2022.105461_bib124","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1073\/pnas.77.10.6124","article-title":"Delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees","volume":"77","author":"Rizzetto","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2022.105461_bib125","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/S0140-6736(80)91678-5","article-title":"Epidemiology of hbv-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused hbsag carriers","volume":"315","author":"Rizzetto","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2022.105461_bib126","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/hep.27585","article-title":"Pegylated interferon therapy of chronic hepatitis D: in need of revision","volume":"61","author":"Rizzetto","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib127","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7326\/0003-4819-98-4-437","article-title":"Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment","volume":"98","author":"Rizzetto","year":"1983","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2022.105461_bib128","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3390\/v13091799","article-title":"HDV Seroprevalence in HBsAg-positive patients in China occurs in hotspots and is not associated with HCV mono-infection","volume":"13","author":"Roggenbach","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2022.105461_bib129","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2022.105461_bib130","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1128\/jvi.67.6.3281-3287.1993","article-title":"Ribonucleoprotein complexes of hepatitis delta virus","volume":"67","author":"Ryu","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib131","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hep.1840210211","article-title":"Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis","volume":"21","author":"Samuel","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib132","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0168-8278(87)80032-6","article-title":"Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection","volume":"5","author":"Saracco","year":"1987","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2022.105461_bib134","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.3390\/molecules15074773","article-title":"Solid-phase synthesis of the lipopeptide Myr-HBVpreS\/2-78, a hepatitis B virus entry inhibitor","volume":"15","author":"Schieck","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.antiviral.2022.105461_bib135","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.26211","article-title":"Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts","volume":"58","author":"Schieck","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2022.105461_bib136","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.13656","article-title":"Towards HBV curative therapies","volume":"38","author":"Schinazi","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2022.105461_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.03.004","article-title":"Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV\/HDV-associated compensated cirrhosis","author":"Schwarz","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib138","article-title":"Interaction of nucleic acid polymers with the large and small forms of the hepatitis delta antigen protein","volume":"66","author":"Shamur","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib139","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1128\/jvi.63.3.1428-1430.1989","article-title":"Self-ligating RNA sequences on the antigenome of human hepatitis delta virus","volume":"63","author":"Sharmeen","year":"1989","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.antiviral.2022.105461_bib141","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side effects of interferon-alpha therapy","volume":"27","author":"Sleijfer","year":"2005","journal-title":"Pharm. World Sci."},{"key":"10.1016\/j.antiviral.2022.105461_bib142","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.27694","article-title":"Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout mice","volume":"62","author":"Slijepcevic","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib143","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(82)90156-8","article-title":"Influence of delta infection on severity of hepatitis B","volume":"2","author":"Smedile","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2022.105461_bib144","first-page":"237","article-title":"Epidemiological and clinical features of fulminant delta hepatitis","volume":"143","author":"Smedile","year":"1983","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.antiviral.2022.105461_bib145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000017","article-title":"IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo","volume":"4","author":"Sommereyns","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2022.105461_bib146","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jhep.2020.06.039","article-title":"Reply to: \u201cRevisiting the estimation of hepatitis D global prevalence","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib147","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib148","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1128\/jvi.67.1.366-372.1993","article-title":"Role of the large hepatitis B virus envelope protein in infectivity of the hepatitis delta virion","volume":"67","author":"Sureau","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib149","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.jhep.2016.02.013","article-title":"The hepatitis delta virus: replication and pathogenesis","volume":"64","author":"Sureau","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib150","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03250-19","article-title":"Snake deltavirus utilizes envelope proteins of different viruses to generate infectious particles","volume":"11","author":"Szirovicza","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2022.105461_bib151","doi-asserted-by":"crossref","first-page":"a021568","DOI":"10.1101\/cshperspect.a021568","article-title":"Hepatitis D virus replication","volume":"5","author":"Taylor","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.antiviral.2022.105461_bib152","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib153","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","article-title":"Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development","volume":"73","author":"Tout","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib154","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/JVI.01034-09","article-title":"Modification of small hepatitis delta virus antigen by SUMO protein","volume":"84","author":"Tseng","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib155","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1128\/JVI.00428-08","article-title":"Transcription of subgenomic mRNA of hepatitis delta virus requires a modified hepatitis delta antigen that is distinct from antigenomic RNA synthesis","volume":"82","author":"Tseng","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib156","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2022.105461_bib157","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/apt.16807","article-title":"Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus","volume":"55","author":"Usai","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2022.105461_bib158","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/acsinfecdis.8b00156","article-title":"REP 2139: antiviral mechanisms and applications in achieving functional control of HBV and HDV infection","volume":"5","author":"Vaillant","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.antiviral.2022.105461_bib159","doi-asserted-by":"crossref","first-page":"S517","DOI":"10.1016\/S0168-8278(18)31283-2","article-title":"Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a","volume":"68","author":"Vaillant","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000928","article-title":"Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis","volume":"6","author":"Vartanian","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2022.105461_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105250","article-title":"Loss of hepatitis D virus infectivity upon farnesyl transferase inhibitor treatment associates with increasing RNA editing rates revealed by a new RT-ddPCR method","volume":"198","author":"Verrier","year":"2022","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2022.105461_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2012.12.008","article-title":"The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus","volume":"58","author":"Volz","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib163","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.1128\/jvi.68.10.6363-6371.1994","article-title":"Packaging of hepatitis delta virus RNA via the RNA-binding domain of hepatitis delta antigens: different roles for the small and large delta antigens","volume":"68","author":"Wang","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib164","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/323508a0","article-title":"Structure, sequence and expression of the hepatitis delta (delta) viral genome","volume":"323","author":"Wang","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2022.105461_bib165","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1073\/pnas.0704000104","article-title":"Involvement of host cellular multivesicular body functions in hepatitis B virus budding","volume":"104","author":"Watanabe","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2022.105461_bib166","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.dld.2022.01.047","article-title":"Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study","volume":"54","author":"Wedemeyer","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.antiviral.2022.105461_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(18)30224-1","article-title":"Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV\/HDV co-infection","volume":"68","author":"Wedemeyer","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib168","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrgastro.2009.205","article-title":"Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead","volume":"7","author":"Wedemeyer","year":"2010","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib169","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0168-8278(17)30310-0","article-title":"PS-039 - a phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the Lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study","volume":"66","author":"Wedemeyer","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib170","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S0618-8278(19)30141-0","article-title":"GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV\/HDV co-infection","volume":"70","author":"Wedemeyer","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib171","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2022.105461_bib172","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.antiviral.2022.105461_bib173","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/jvi.62.2.594-599.1988","article-title":"A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta","volume":"62","author":"Weiner","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib174","doi-asserted-by":"crossref","first-page":"E720","DOI":"10.3390\/v10120720","article-title":"A divergent hepatitis D-like agent in birds","volume":"10","author":"Wille","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2022.105461_bib175","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1365-2893.2012.01597.x","article-title":"Large hepatitis delta antigen activates STAT-3 and NF-\u03baB via oxidative stress","volume":"19","author":"Williams","year":"2012","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2022.105461_bib176","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1099\/vir.0.011239-0","article-title":"Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha\/beta interferon-inducible MxA gene","volume":"90","author":"Williams","year":"2009","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2022.105461_bib177","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/hep.30815","article-title":"Analysis of host responses to hepatitis B and delta viral infections in a micro-scalable hepatic Co-culture system","volume":"71","author":"Winer","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib178","doi-asserted-by":"crossref","first-page":"15118","DOI":"10.1073\/pnas.232416799","article-title":"Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1","volume":"99","author":"Wong","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2022.105461_bib179","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.1057925","article-title":"Stimulation of RNA polymerase II elongation by hepatitis delta antigen","volume":"293","author":"Yamaguchi","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2022.105461_bib180","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"10.1016\/j.antiviral.2022.105461_bib181","first-page":"1","article-title":"Meld score may underestimate disease severity and risk of death in patients with non-alcoholic fatty liver disease","volume":"61","author":"Yardeni","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib182","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","article-title":"Hepatitis delta international network (HDIN)","volume":"70","author":"Yurdaydin","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib183","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0168-8278(02)00162-9","article-title":"Famciclovir treatment of chronic delta hepatitis","volume":"37","author":"Yurdaydin","year":"2002","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib184","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2893.2007.00936.x","article-title":"Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon","volume":"15","author":"Yurdaydin","year":"2008","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2022.105461_bib185","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0168-8278(17)30327-6","article-title":"GS-008 - a phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis-end of treatment results from the LOWR HDV-2 study","volume":"66","author":"Yurdaydin","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib186","first-page":"S89","article-title":"PS-161 - Subanalysis of the LOWR HDV-2 study reveals high response rates to Lonafarnib in patients with low viral loads","author":"Yurdaydin","year":"2018","journal-title":"J. Hepatol. Int. Liver Congress"},{"key":"10.1016\/j.antiviral.2022.105461_bib187","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","article-title":"Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study","volume":"67","author":"Yurdaydin","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2022.105461_bib188","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2893.2010.01353.x","article-title":"Natural history and treatment of chronic delta hepatitis","volume":"17","author":"Yurdayd\u0131n","year":"2010","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2022.105461_bib189","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2018.02.021","article-title":"Hepatitis D virus replication is sensed by MDA5 and induces IFN-\u03b2\/\u03bb responses in hepatocytes","volume":"69","author":"Zhang","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib190","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","author":"Zhang","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2022.105461_bib191","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0969-2126(98)00084-7","article-title":"Structural basis of the oligomerization of hepatitis delta antigen","volume":"6","author":"Zuccola","year":"1998","journal-title":"Structure"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222002303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354222002303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:37:31Z","timestamp":1759063051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354222002303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":191,"alternative-id":["S0166354222002303"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105461","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis D virus: Improving virological knowledge to develop new treatments","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2022.105461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105461"}}